Price Alert

Anebulo Pharmaceuticals I... (ANEB)

NASDAQ: ANEB · Real-Time Price · USD

2.31

-0.09 (-3.75%)

At close: Oct 03, 2025, 3:59 PM

2.31

0.00%

After-hours: Oct 03, 2025, 04:52 PM EDT

-3.75% (1D)

Bid	2.17
Market Cap	94.91M
Revenue (ttm)	n/a
Net Income (ttm)	-7.69M
EPS (ttm)	-0.25
PE Ratio (ttm)	-9.24
Forward PE	-4.98
Analyst	Hold
Dividends	n/a

Ask	2.46
Volume	35,526
Avg. Volume (20D)	432,587
Open	2.38
Previous Close	2.40
Day's Range	2.26 - 2.41
52-Week Range	0.80 - 3.42
Beta	-0.86
Ex-Dividend Date	n/a

About ANEB

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ANEB

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ANEB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 weeks ago

+17.91%

Anebulo Pharmaceuticals shares are trading higher ... Unlock content with Pro Subscription

2 months ago

+81.97%

Anebulo Pharmaceuticals shares are trading higher after the company announced a reverse stock split with a ratio of at least 1-for-2500.

News

5 days ago · businesswire.com

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates.

1 week ago · businesswire.com

Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced ...

2 months ago · businesswire.com

Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic ...